Net Income (Loss) Attributable to Parent of PharmaCyte Biotech, Inc. from 31 Jul 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
PharmaCyte Biotech, Inc. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Jul 2010 to 31 Oct 2025.
  • PharmaCyte Biotech, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Oct 2025 was $7,417,975, a 405% decline year-over-year.
  • PharmaCyte Biotech, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Oct 2025 was $7,073,816, a 131% decline year-over-year.
  • PharmaCyte Biotech, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $30,656,050, a 9085% increase from 2023.
  • PharmaCyte Biotech, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $333,763.
  • PharmaCyte Biotech, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $4,315,993, a 1.8% decline from 2021.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

PharmaCyte Biotech, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,073,816 $7,417,975 -$5,948,415 -405% 01 Aug 2025 31 Oct 2025 10-Q 18 Dec 2025 2026 Q2
Q2 2025 $1,125,401 $8,360,096 -$31,781,451 -136% 01 May 2025 31 Jul 2025 10-Q 18 Dec 2025 2026 Q2
Q1 2025 $30,656,050 $11,749,583 +$10,402,882 +772% 01 Feb 2025 30 Apr 2025 10-K 11 Aug 2025 2025 FY
Q4 2024 $20,253,168 $3,045,328 -$2,425,791 -392% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $22,678,959 $1,469,560 -$4,259,456 -153% 01 Aug 2024 31 Oct 2024 10-Q 18 Dec 2025 2026 Q2
Q2 2024 $26,938,415 $23,421,355 +$26,604,652 01 May 2024 31 Jul 2024 10-Q 18 Dec 2025 2026 Q2
Q1 2024 $333,763 $1,346,701 +$1,473,039 01 Feb 2024 30 Apr 2024 10-K 11 Aug 2025 2025 FY
Q4 2023 $1,139,276 $619,537 +$144,599 +19% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q3
Q3 2023 $1,283,875 $2,789,896 +$4,670,403 01 Aug 2023 31 Oct 2023 10-Q 17 Mar 2025 2025 Q3
Q2 2023 $5,954,278 $3,183,297 -$1,638,285 -106% 01 May 2023 31 Jul 2023 10-Q 17 Mar 2025 2025 Q3
Q1 2023 $4,315,993 $126,338 +$1,296,369 +91% 01 Feb 2023 30 Apr 2023 10-K 13 Aug 2024 2024 FY
Q4 2022 $5,612,362 $764,136 +$47,154 +5.8% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q3
Q3 2022 $5,659,516 $1,880,507 -$900,761 -92% 01 Aug 2022 31 Oct 2022 10-Q 18 Mar 2024 2024 Q3
Q2 2022 $4,758,755 $1,545,012 -$519,594 -51% 01 May 2022 31 Jul 2022 10-Q 18 Mar 2024 2024 Q3
Q1 2022 $4,239,161 $1,422,707 -$462,703 -48% 01 Feb 2022 30 Apr 2022 10-K 31 Jul 2023 2023 FY
Q4 2021 $3,776,458 $811,290 -$54,194 -7.2% 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023 2023 Q3
Q3 2021 $3,722,264 $979,746 -$29,554 -3.1% 01 Aug 2021 31 Oct 2021 10-Q 16 Mar 2023 2023 Q3
Q2 2021 $3,692,710 $1,025,418 -$141,474 -16% 01 May 2021 31 Jul 2021 10-Q 16 Mar 2023 2023 Q3
Q1 2021 $3,551,236 $960,004 -$209,621 -28% 01 Feb 2021 30 Apr 2021 10-K 28 Jul 2022 2022 FY
Q4 2020 $3,341,615 $757,096 +$118,212 +14% 01 Nov 2020 31 Jan 2021 10-Q 15 Mar 2022 2022 Q3
Q3 2020 $3,459,827 $950,192 +$116,930 +11% 01 Aug 2020 31 Oct 2020 10-Q 15 Mar 2022 2022 Q3
Q2 2020 $3,576,757 $883,944 +$250,131 +22% 01 May 2020 31 Jul 2020 10-Q 15 Mar 2022 2022 Q3
Q1 2020 $3,826,888 $750,383 +$388,561 +34% 01 Feb 2020 30 Apr 2020 10-K 10 Aug 2021 2021 FY
Q4 2019 $4,215,449 $875,308 -$198,961 -29% 01 Nov 2019 31 Jan 2020 10-Q 12 Mar 2021 2021 Q3
Q3 2019 $4,016,488 $1,067,122 -$30,548 -2.9% 01 Aug 2019 31 Oct 2019 10-Q 11 Dec 2020 2021 Q2
Q2 2019 $3,985,940 $1,134,075 +$81,288 +6.7% 01 May 2019 31 Jul 2019 10-Q 11 Sep 2020 2021 Q1
Q1 2019 $4,067,228 $1,138,944 +$156,524 +12% 01 Feb 2019 30 Apr 2019 10-K 13 Aug 2020 2020 FY
Q4 2018 $4,223,752 $676,347 +$1,354,313 +67% 01 Nov 2018 31 Jan 2019 10-Q 13 Mar 2020 2020 Q3
Q3 2018 $5,578,065 $1,036,574 +$777,724 +43% 01 Aug 2018 31 Oct 2018 10-Q 13 Mar 2020 2020 Q3
Q2 2018 $6,355,789 $1,215,363 +$473,052 +28% 01 May 2018 31 Jul 2018 10-Q 13 Mar 2020 2020 Q3
Q1 2018 $6,828,841 $1,295,468 -$140,446 -12% 01 Feb 2018 30 Apr 2018 10-K 13 Aug 2019 2019 FY
Q4 2017 $6,688,395 $2,030,660 -$748,514 -58% 01 Nov 2017 31 Jan 2018 10-Q 14 Mar 2019 2019 Q3
Q3 2017 $5,939,881 $1,814,298 -$839,747 -86% 01 Aug 2017 31 Oct 2017 10-Q 14 Mar 2019 2019 Q3
Q2 2017 $5,100,134 $1,688,415 -$656,449 -64% 01 May 2017 31 Jul 2017 10-Q 14 Mar 2019 2019 Q3
Q1 2017 $4,443,685 $1,155,022 -$32,955 -2.9% 01 Feb 2017 30 Apr 2017 10-K 27 Jul 2017 2017 FY
Q4 2016 $4,410,730 $1,282,146 +$508,951 +28% 01 Nov 2016 31 Jan 2017 10-Q 19 Mar 2018 2018 Q3
Q3 2016 $4,919,681 $974,551 +$661,031 +40% 01 Aug 2016 31 Oct 2016 10-Q 14 Dec 2017 2018 Q2
Q2 2016 $5,580,712 $1,031,966 +$483,072 +32% 01 May 2016 31 Jul 2016 10-Q 13 Sep 2017 2017 Q1
Q1 2016 $6,063,784 $1,122,067 +$2,898,322 +72% 01 Feb 2016 30 Apr 2016 10-K 27 Jul 2017 2017 FY
Q4 2015 $8,962,106 $1,791,097 -$333,047 -23% 01 Nov 2015 31 Jan 2016 10-K 27 Jul 2017 2017 FY
Q3 2015 $8,629,059 $1,635,582 +$1,228,861 +43% 01 Aug 2015 31 Oct 2015 10-K 27 Jul 2017 2017 FY
Q2 2015 $9,857,920 $1,515,038 +$69,786 +4.4% 01 May 2015 31 Jul 2015 10-K 27 Jul 2017 2017 FY
Q1 2015 $9,927,706 $4,020,389 +$12,450,422 +76% 01 Feb 2015 30 Apr 2015 10-K 29 Jul 2016 2016 FY
Q4 2014 $22,378,128 $1,458,050 -$999,278 -218% 01 Nov 2014 31 Jan 2015 10-K 29 Jul 2016 2016 FY
Q3 2014 $21,378,850 $2,864,443 +$2,793,627 +49% 01 Aug 2014 31 Oct 2014 10-K 29 Jul 2016 2016 FY
Q2 2014 $24,172,477 $1,584,824 +$3,081,543 +66% 01 May 2014 31 Jul 2014 10-K 29 Jul 2016 2016 FY
Q1 2014 $27,254,020 $16,470,811 -$16,142,885 -4923% 01 Feb 2014 30 Apr 2014 10-K/A 19 Jan 2016 2015 FY
Q4 2013 $11,111,135 $458,772 -$81,929 -22% 01 Nov 2013 31 Jan 2014 10-K/A 19 Jan 2016 2015 FY
Q3 2013 $11,029,206 $5,658,070 -$5,275,254 -1378% 01 Aug 2013 31 Oct 2013 10-K/A 19 Jan 2016 2015 FY
Q2 2013 $5,753,952 $4,666,367 -$4,155,850 -814% 01 May 2013 31 Jul 2013 10-K/A 19 Jan 2016 2015 FY
Q1 2013 $1,598,102 $327,926 +$176,435 +35% 01 Feb 2013 30 Apr 2013 10-K/A 19 Jan 2016 2015 FY
Q4 2012 $1,774,537 $376,843 -$105,064 -39% 01 Nov 2012 31 Jan 2013 10-Q 17 Mar 2014 2014 Q3
Q3 2012 $1,669,473 $382,816 +$54,336 +12% 01 Aug 2012 31 Oct 2012 10-Q 16 Dec 2013 2014 Q2
Q2 2012 $1,723,809 $510,517 +$175,503 +26% 01 May 2012 31 Jul 2012 10-Q 16 Sep 2013 2014 Q1
Q1 2012 $1,899,312 $504,361 +$589,174 +54% 01 Feb 2012 30 Apr 2012 10-K 29 Jul 2013 2013 FY
Q4 2011 $2,488,486 $271,779 -$147,678 -119% 01 Nov 2011 31 Jan 2012 10-Q 26 Mar 2013 2013 Q3
Q3 2011 $2,340,808 $437,152 -$391,332 -854% 01 Aug 2011 31 Oct 2011 10-Q 26 Dec 2012 2013 Q2
Q2 2011 $1,949,476 $686,020 -$551,760 -411% 01 May 2011 31 Jul 2011 10-Q 19 Sep 2012 2013 Q1
Q1 2011 $1,397,716 $1,093,535 01 Feb 2011 30 Apr 2011 10-K 14 Aug 2012 2012 FY
Q4 2010 $124,101 01 Nov 2010 31 Jan 2011 10-Q 21 Mar 2012 2012 Q3
Q3 2010 $45,820 01 Aug 2010 31 Oct 2010 10-Q 15 Dec 2011 2012 Q2
Q2 2010 $134,260 01 May 2010 31 Jul 2010 10-Q/A 20 Sep 2011 2012 Q1

PharmaCyte Biotech, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $30,656,050 +$30,322,287 +9085% 01 May 2024 30 Apr 2025 10-K 11 Aug 2025 2025 FY
2023 $333,763 +$4,649,756 01 May 2023 30 Apr 2024 10-K 11 Aug 2025 2025 FY
2022 $4,315,993 -$76,832 -1.8% 01 May 2022 30 Apr 2023 10-K 13 Aug 2024 2024 FY
2021 $4,239,161 -$687,925 -19% 01 May 2021 30 Apr 2022 10-K 31 Jul 2023 2023 FY
2020 $3,551,236 +$275,652 +7.2% 01 May 2020 30 Apr 2021 10-K 28 Jul 2022 2022 FY
2019 $3,826,888 +$240,340 +5.9% 01 May 2019 30 Apr 2020 10-K 10 Aug 2021 2021 FY
2018 $4,067,228 +$2,761,613 +40% 01 May 2018 30 Apr 2019 10-K 13 Aug 2020 2020 FY
2017 $6,828,841 -$2,385,156 -54% 01 May 2017 30 Apr 2018 10-K 13 Aug 2019 2019 FY
2016 $4,443,685 +$1,620,099 +27% 01 May 2016 30 Apr 2017 10-K 20 Jul 2018 2018 FY
2015 $6,063,784 +$3,863,922 +39% 01 May 2015 30 Apr 2016 10-K 27 Jul 2017 2017 FY
2014 $9,927,706 +$17,326,314 +64% 01 May 2014 30 Apr 2015 10-K 29 Jul 2016 2016 FY
2013 $27,254,020 -$25,655,918 -1605% 01 May 2013 30 Apr 2014 10-K 29 Jul 2016 2016 FY
2012 $1,598,102 +$301,210 +16% 01 May 2012 30 Apr 2013 10-K/A 19 Jan 2016 2015 FY
2011 $1,899,312 -$501,596 -36% 01 May 2011 30 Apr 2012 10-K 29 Jul 2013 2013 FY
2010 $1,397,716 01 May 2010 30 Apr 2011 10-K 14 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.